The small to mid market cap biotech/healthcare section of the market has had a banner year in 2019 with numerous stocks enjoying the benefit of success in the clinic (Paradigm Biopharmaceuticals) as well as regulatory and commercialisation success (Avita Medical). Among the medical device stocks and those with an exposure to healthcare IT, Nanosonics, Promedicus and Volpara Health Technology have each enjoyed significant gains in market share and revenue growth.

Turning to the outlook for 2020 and a predominantly new group of stocks are included in our key picks including Oncosil Medical and Botanix Pharmaceuticals. Both are undervalued in our view with significant news flow likely in 2020.

Longer term we believe stocks developing gene therapies will be at the cutting edge of new drug development over the next decade. These drugs have the potential to cure previously untreatable disease including many debilitating inherited genetic conditions of which there are thousands. In our stock coverage the company with the nearest term drug candidates (albeit still pre-clinical) is Avita Medical (AVH).


Following a long period of sustained effort, Oncosil Medical is finally on the verge of obtaining a CE Mark in Europe. This should lead to first commercial revenues in 2020. Oncosil has a brachytherapy device for the treatment of inoperable pancreatic cancer as well as for use in down staging of borderline cases such that patients become eligible for surgical cure.

Data from the 42 patient trial conducted in Europe and Australia demonstrated an impressive survival benefit compared to patients treated with the standard of care. The overall survival benefit is at least 3 months with 50% of patients still alive and in long term follow up.

We expect the company will receive a humanitarian device exemption in the United States in 2020 and this is likely to be followed by a larger clinical program at some point.


Botanix Pharmaceuticals is an Australian biotech company engaged in the development of novel compounds for the treatment of a range of dermatological conditions. All products utilise synthetic cannabidiol (CBD) in conjunction with Permetrex skin delivery technology. The company has exclusive rights to this technology for all drugs that treat dermatology conditions. The first two indications are for chronic acne and atopic dermatitis (AD). Botanix recently reported results from a phase II trial in the treatment of moderate to severe acne. The trial did not meet the primary clinical endpoints, nevertheless we believe extenuating circumstances contributed materially to this outcome, namely the US DEA restrictions regarding the transport and storage of drugs involved in the trial. These restrictions have now been relaxed and will allow for a much tighter level of control in subsequent clinical programs. The results from the Australian sites were in line with earlier testing and are supportive of further analysis.The company’s approach to testing and registration of this controversial new class of drug is no different to any new chemical entity. Feedback from clinicians and patients involved in the clinical program has been highly encouraging with the safety aspect of the drug representing a significant advantage over competitors.

Authored by John Hester – Health Care & Biotech Analyst at Bell Potter Securities, 17 December 2019
Important Disclaimer—This may affect your legal rights: Because this document has been prepared without consideration of any specific client’s financial situation, particular needs and investment objectives, a Bell Potter Securities Limited investment adviser (or the financial services licensee, or the proper authority of such licensee, who has provided you with this report by arrangement with Bell Potter Securities Limited) should be consulted before any investment decision is made. While this document is based on the information from sources which are considered reliable, Bell Potter Securities Limited, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. Nor does Bell Potter Securities Limited accept any responsibility to inform you of any matter that subsequently comes to its notice, which may affect any of the information contained in this document. This document is a private communication to clients and is not intended for public circulation or for the use of any third party, without the prior approval of Bell Potter Securities Limited. In the USA and the UK this research is only for institutional investors. It is not for release, publication or distribution in whole or in part to any persons in the two specified countries. This is general investment advice only and does not constitute advice to any person.
Disclosure of Interest: Bell Potter Securities Limited receives commission from dealing in securities and its authorised representatives, or introducers of business, may directly share in this commission. Bell Potter Securities and its associates may hold shares in the companies recommended.
Botanix Pharmaceuticals (BOT):
Bell Potter acted as lead manager of the BOT’s August 2019 capital raise for $40m and received fees for that service.